A Fundamental Difference in Philosophy
At the heart of the India-US divide on Intellectual Property (IP) is a philosophical chasm. The United States, home to many of the world's largest pharmaceutical, software, and entertainment corporations, champions a maximalist view. It sees IP rights
as private property, crucial for incentivizing innovation and deserving of the strongest possible protection globally. From this perspective, any dilution of these rights is a threat to economic competitiveness and future research and development. India, conversely, views IP through the prism of public policy and national development. As a developing economy with vast public health needs, India has structured its laws to balance innovator rights with public interest, utilizing flexibilities within international trade law to prioritize access and affordability. This has positioned India as 'the pharmacy of the world' but also placed it in direct conflict with the US position.
Pharmaceuticals: The Primary Battleground
Nowhere is this conflict more visible than in the pharmaceutical sector. A key point of contention is Section 3(d) of India's Patents Act. This provision prevents 'evergreening', a practice where companies make minor modifications to existing drugs to secure new patents and extend their monopolies. Section 3(d) requires that a new form of a known substance must show a significant increase in therapeutic efficacy to be patentable. US pharmaceutical lobbies argue this standard is subjective, stifles innovation, and unfairly invalidates patents. Another major friction point is compulsory licensing. Indian law allows the government to grant licenses to domestic manufacturers to produce a patented drug without the patent holder's consent, particularly if the drug is deemed unaffordably priced or inaccessible. While India has used this provision only once, the very existence of the law is seen by US trade bodies as a significant threat to their commercial interests.
The 'Special 301' Report and US Pressure
The primary tool the US uses to exert pressure on this issue is the annual 'Special 301 Report', published by the United States Trade Representative (USTR). For years, India has been placed on the 'Priority Watch List'. This designation signals that the US believes a country has serious deficiencies in its IP protection and enforcement regime. The 2026 report continues this trend, citing ongoing concerns about India's patent laws, weak enforcement against counterfeiting and piracy, and rules that create uncertainty for innovators. While placement on the list does not trigger automatic sanctions, it functions as a significant diplomatic pressure tactic and a formal declaration of US dissatisfaction, framing the narrative for all bilateral trade discussions.
Beyond Pharma: The New Digital Frontier
The IP dispute is no longer confined to medicine. The digital economy has opened up new fronts in the disagreement. A major issue is data localization, where India has pursued policies requiring certain types of data to be stored within the country's geographical boundaries. The Indian government argues this is necessary for national security, data sovereignty, and effective law enforcement. However, US tech giants and the USTR argue that these rules are protectionist trade barriers that increase operational costs, force the construction of redundant infrastructure, and hinder the free flow of information that the digital economy relies on. Other digital issues, such as copyright protection for online content and proposed rules for developers using copyrighted works for AI training, have also emerged as significant points of friction.
